Quantification of [(18)F]afatinib using PET/CT in NSCLC patients: a feasibility study

INTRODUCTION: Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [(18)F]afatinib using positron emission tomography (PET) may identify those patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Stadt, E. A., Yaqub, M., Lammertsma, A. A., Poot, A. J., Schober, P. R., Schuit, R. C., Smit, E. F., Bahce, I., Hendrikse, N. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431492/
https://www.ncbi.nlm.nih.gov/pubmed/32804306
http://dx.doi.org/10.1186/s13550-020-00684-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431492/
https://www.ncbi.nlm.nih.gov/pubmed/32804306
http://dx.doi.org/10.1186/s13550-020-00684-4

Ejemplares similares